Brief timeline and flunding history 2011 Fluxion Biosciences

Fluxion today • Company: – Venture backed since Dec 2007 – 4 products commercialized and selling globally – Segment: Biotools – Over 100 units installed • Products: instruments and consumables – Bio. Flux System for cell-cell interactions – Ion. Flux Automated Patch Clamp System – Iso. Flux rare cell isolation platform – under development Bio. Flux 200 Bio. Flux 1000 © 2011 Fluxion Biosciences. All rights reserved. Ion. Flux-16 Ion. Flux HT Page 2

Partial customer list Johnson & Johnson © 2011 Fluxion Biosciences. All rights reserved. Page

Ion. Flux applications • Compound profiling – Dose response measurements – Hit confirmation – Single concentration screening • Mutant screening – Evaluate functional changes dependent on mutations – Record responses from up to 32 distinct mutants (8 for IF-HT) • Structure-function studies – – Determine the effect of mutations on channel function Characterize expression for differentiated stem cells Recording endogenously expressed ion channels Screen clones based on ion channel density © 2011 Fluxion Biosciences. All rights reserved. Page 4

Ion. Flux Technology for APC - Best in Class • High quality data – G-seal quality recordings – Ensemble recording for improved success rate • Cost effective – Perform APC for about the cost of an MPC setup • Simple to use – Ease of use of a ‘plate reader’ – Relevance of patch clamp data – Table top unit • Reliable – No robotics required – Only two moving parts © 2011 Fluxion Biosciences. All rights reserved. Page 5

Ensemble vs. single cell recording • Ensembles average signals over 20 patched cells (16 ensembles per plate, left panel) • The new single cell consumable records from one cell per channel (16 cells per plate for IF-16, right panel) • The single cell consumable utilizes the same hardware 20 -cell ensemble © 2011 Fluxion Biosciences. All rights reserved. Single cell Page 6

Well-Plate Integrated Microfluidics Well-plate integrated microfluidics (WPM) utilizes standard 96 - and 384 -well plates, but the bottom of the plate is replaced with a microfluidic network interconnected between the wells. © 2010 2011 Fluxion Biosciences. All rights reserved. Page 7

* Sample customer slide – Pfizer UK © 2011 Fluxion Biosciences. All rights reserved.

High Level Timeline Grant 2 Ph 1 Founded 2006 Grant 2 Ph 2 2007 2008 Grant 1 Ph 2 Grant 1 Ph 1 2009 2010 2011 Ion. Flux product launch Bio. Flux product launch Series A © 2011 Fluxion Biosciences. All rights reserved. Series B Page 9

Grant pipeline and success rates © 2011 Fluxion Biosciences. All rights reserved. Page 10

SBIR: the good, the bad and the ugly • The good: – Non-dilutive capital! – Can be the catalyst for new projects, encourages innovation – Early $$, which are the hardest • The bad: – Long timelines: 9 mo. from application to funding – <200 k is low capital for Phase I awards – Can be a distraction from the central mission • The ugly: – Review process dependent on random events – In our case, projects with the greatest commercial worth didn’t get funded © 2011 Fluxion Biosciences. All rights reserved. Page 11